Friday, 13 Jul 2018

You are here

Mortality in Gout Increased

Two current articles in the Journal of Rheumatology address issues surrounding mortality risk among those with new and established gout.

Vincent et al assessed predictors of mortality in patients with a recent onset of gout (disease duration < 10 years). They analyzed 295 patients with a mean followup duration of 5.1 years, during which time there were 43 deaths (14.6%).

Factors independently associated with an increased mortality risk included: older age (HR > 9.3 for those over 80 yrs.); Māori or Pacific ethnicity (HR 2.48); loop diuretic use (HR 3.99); elevated serum creatinine and the tophi (HR 2.85).  Amongst these only subcutaneous tophi was the only baseline variable independently associated with both CV death and all cause death.

A gout disease duration < 10 years has an increased risk of death. Subcutaneous tophi at baseline is an independent predictor of mortality, from both CV and non-CV causes.

Kang and Korean investigators also analyzed mortality risk in terms of gender and serum urate (SUA) levels. (Citation source: http://buff.ly/2omFieW

During 12.3 years of followup there was 27,490 deaths, amounting to 6.9% of men and 3.1% of women died.

The bimodal (U shaped) association between SUA levels in men and mortality was not seen in women. Thus a significant interaction of gender was seen with the SUA-mortality association.

Thus a higher mortality rate was seen with very low SUA levels (SUA ≤ 4.0 mg/dl, adjusted HR 1.413) and higher SUA levels in men (> 8.0 mg/dl, adjusted HR 1.140). Women failed to show any significant association between SUA and mortality.

Novel to this study was the observation that lower SUA (after correction) was an independent risk factor for all-cause mortality in men with normal kidney function.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Obesity, Hypertension and Diuretics Drive Gout Risk

A recent metanalysis suggests that obesity, hypertension and diuretic use are associated with a two-fold increased risk of incident gout.

From a potential of 9923 articles, researchers analyzed 11 studies with data suitable for the meta-analysis.

Gout was 2.24 times more likely to occur in individuals with body mass index ≥ 30 kg/m2 (adjusted relative risk 2.24 (95% confidence interval) 1.76–2.86).

Public Citizen Pressures FDA to Pull Febuxostat

Public Citizen has petitioned the U.S. Food and Drug Administration (FDA) to remove Takeda's drug febuxostat (Uloric) from the market, citing the FDA's own warnings and evidence of serious cardiovascular harms. This follows on a recent FDA safety warning and NEJM paper citing cardiovascular concerns over febuxostat.

Gout Takeaways

The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.

Sons of Gout Study

The genetics and heritability of gout has suggested a higher risk in certain families.  A UK cohort study examined the prevalence of gout and monosodium urate (MSU) crystal deposition among those at risk (sons of gout patients) for gout and found a high incidence of hyperuricemia and MSU crystal deposition.

The Hazardous Highs and Lows of Uric Acid

Both high and low levels of uric acid were linked with increased risks of death, showing a U-shaped association between serum uric acid levels and all-cause, cardiovascular, and cancer mortality, Korean researchers reported.